Release Date: 12-Jul-2024
At present, it is estimated that over 700 bispecific antibodies are in development, with a majority of these being in preclinical development, followed by those still under research. Bispecific antibodies for solid cancers currently make up for a majority of the candidates under development overall, those for hematological cancers dominate clinical trials. The US is largely dominating the research and development landscape of bispecific antibodies, followed by China, given by the extensive research efforts and investment put in players in these regional markets. These trends are expected to continue into the near future, suggesting that the bispecific antibodies are commercially a lucrative avenue for development.
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market